Italfarmaco, JCR Pharma Ink Deal for Hunter Syndrome Therapy
Italfarmaco and JCR Pharmaceuticals announced an exclusive license agreement for the development and commercialization of JR-141, an investigational therapy for Hunter Syndrome, in the United States, Europe, and Latin America.